Showing 651-660 of 9358 results for "".
- Meet the Newest AAD Officers and Board Membershttps://practicaldermatology.com/news/meet-the-newest-aad-officers-and-board-members/2457876/Suzanne M. Olbricht, MD, FAAD, a Boston-based dermatologist, will take the helm of the American Academy of Dermatology (AAD) as the new President. Her one-year term officially begins on Tuesday, Feb. 20, at the conclusion of the 2018 AAD Annual Meeting in San Diego. Dr. Olbricht is an associate pr…
- Upadacitinib Linked with Improvement for Hand Eczema in Patients with Atopic Dermatitishttps://practicaldermatology.com/news/updacitinib-shows-promise-for-ad-and-hand-eczema-in-trial/2462198/Results from a new study suggest that upadacitinib is efficacious for the treatment of hand eczema (HE) and atopic dermatitis (AD) in patients with AD. The study authors, publishing in Contact Dermatitis, included a total of 38 patients in the observational cohort analysis (32 of whom had HE) fro…
- It's Official: April Is the Coolest Month of the Yearhttps://practicaldermatology.com/news/its-official-april-is-the-coolest-month-of-the-year/2461642/April 2023 marks the first-ever CoolMonth, according to Allergan Aesthetics, an AbbVie company and the parent company of CoolSculpting Elite. Why April? A survey revealed 85% of people have a season in which they begin to think more about getting rid of stubborn body fat, and for 40% of those pe…
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinit…
- NEA Introduces New “Focus on Eczema” Campaign for Eczema Awareness Month 2022https://practicaldermatology.com/news/nea-introduces-new-focus-on-eczema-campaign/2461367/The National Eczema Association (NEA) is rolling out its annual Eczema Awareness Month campaign with an innovative look at the life-altering, non-contagious and inflammatory skin disease that burdens 31.6 million adults and children in the United States (10.1% of the population). Themed "Focus …
- Rodan + Fields Gives Back: Company Announces More Donations from Youth Empowerment Fundhttps://practicaldermatology.com/news/rodan-fields-gives-back-company-announces-more-donations-from-youth-empowerment-fund/2461300/Rodan + Fields has announced the second round of donations from the Youth Empowerment Fund through their support of the Prescription for Change project. Launched in August 2021, the Fund will invest a total of $5 Million over three years to empower young people to lead social and environmental ch…
- Practical Dermatology® Names New Interim Digital Practice Editorhttps://practicaldermatology.com/news/practical-dermatology-names-new-interim-digital-practice-editor/2461145/Practical Dermatology® magazine is proud to announce that Vishal Anil Patel, MD will serve as interim editor of our Digital Practice column. Dr. Patel is director of cutaneous oncology at GW Cancer Center, director of dermatologic surgery at GW department of dermatology, and an assistant professo…
- Researchers Define Keys to Recognizing Ocular Rosaceahttps://practicaldermatology.com/news/researchers-define-keys-to-recognizing-ocular-rosacea-1/2461052/A number of eye symptoms may be more common in patients with rosacea compared to those without the skin disease, but the presence of conjunctival telangiectases may be the eye symptom most closely associated with rosacea. Findings come from a study in which researchers evaluated the right eyes of …
- Tapinarof Improves Plaque Psoriasis in Phase 3 Trialshttps://practicaldermatology.com/news/tapinarof-improves-plaque-psoriasis-in-phase-3-trials/2461004/Tapinarof performed well in two Phase 3 plaque psoriasis trials, according to research published in the New England Journal of Medicine. “This study reports that topical tapinarof cream, a new nonsteroidal cream for plaque psoriasis, is highly effective,” says study author Mark Lebwohl, MD, FAAD, …
- FDA Approves Cyltezo as First Interchangeable Biosimilar with Humirahttps://practicaldermatology.com/news/fda-approves-cyltezo-as-first-interchangeable-biosimilar-with-humira/2460957/The FDA approved the supplemental Biologics License Application (sBLA) for Boehringer Ingelheim's Cyltezo (adalimumab-adbm) as the first Interchangeable biosimilar with Humira (adalimumab). The FDA originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases and t…